Biotech Stocks: 5 Biggest Companies in 2023

dna strand 3d rendering
Timofeev Vladimir / Shutterstock

What are the biggest names in biotechnology? We count down the five top biotech stocks based on market cap.

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in countries all around the globe.

Plus, these big-name biotech players have pipelines stuffed with potentially disruptive products — and enough revenue to recover should some of those products fail.

This means that investors can experience the excitement of biotech investing while minimizing risk. Although returns are never guaranteed, company size can insulate investors from volatility.

Which biotech companies should investors consider?

If you’re cautiously interested in biotech stocks, starting with the top companies by market cap could be a good strategy. This list of the largest NASDAQ biotech stocks was compiled using’s stock screener, and all numbers were current as of April 27, 2023. NYSE biotech stocks were considered as well, but did not make the cut.

1. Vertex Pharmaceuticals (NASDAQ:VRTX)

Market capitalization: US$86.33 billion

Vertex Pharmaceuticals is a global biotech firm focused on developing and commercializing therapies for treating cystic fibrosis. It has a number of approved treatments for cystic fibrosis, and a pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes.

Vertex and its partner CRISPR Therapeutics (NASDAQ:CRSP) have submitted biologics license applications to the US Food and Drug Administration (FDA) for drug candidate CTX001 as a treatment for severe sickle cell disease and transfusion-dependent beta thalassemia.

2. Regeneron Pharmaceuticals (NASDAQ:REGN)

Market capitalization: US$84.52 billion

Biotech leader Regeneron Pharmaceuticals develops and commercializes medicines targeting cancer, pain and a wide variety of diseases, including inflammatory, cardiovascular, metabolic, hematologic and rare diseases.

The FDA has approved nine of the treatments in the company’s portfolio, which also includes a number of product candidates in development. The company’s Regeneron Genetics Center is investigating approaches to speeding up the discovery and development of medicines for serious illnesses. In late May 2022, Regeneron acquired immuno-oncology company Checkmate Pharmaceuticals, whose lead investigational candidate, vidutolimod, has demonstrated clinical responses as a monotherapy in patients with PD-1 refractory melanoma.

The FDA is expected to make a decision in June 2023 on Regeneron’s biologics license application for Eylea (aflibercept) targeting wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.

3. Moderna (NASDAQ:MRNA)

Market capitalization: US$50.1 billion

Best known today for the rapid deployment of effective COVID-19 vaccines, Moderna leads the world in the field of mRNA-based medicine. Alongside a diverse clinical and intellectual property portfolio targeting infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases, the company’s assets include an integrated manufacturing plant that allows for both clinical and commercial production.

The biotechnology and pharmaceutical company recently partnered with technology giant IBM (NYSE:IBM) to explore the use of quantitive computing and generative artificial intelligence in developing mRNA medicines.

4. Seagen (NASDAQ:SGEN)

Market capitalization: US$37.67 billion

Seagen is developing and commercializing monoclonal antibody-based therapies for the treatment of cancer. The biotech company's product pipeline includes at least nine Phase 3 clinical studies covering four drug candidates, with a focus on several forms of cancer, including cervical, breast, colorectal, bladder and large B cell lymphoma.

In April 2023, the FDA granted accelerated approval for Seagen’s PADCEV (enfortumab vedotin-ejfv) with KEYTRUDA (pembrolizumab) for the first-line treatment of locally advanced or metastatic urothelial cancer.


Market capitalization: US$26.72 billion

Biopharmaceutical firm BioNTech is advancing immunotherapies for serious diseases such as cancer. The company’s portfolio of oncology product candidates includes mRNA-based therapies, CAR-T cell therapies and targeted cancer antibodies. In partnership with Pfizer (NYSE:PFE), BioNTech brought to market one of the world’s most important COVID-19 vaccines.

Recently, BioNTech inked a potential US$1.67 billion collaboration deal with China-based biotech company Duality Biologics. Under the agreement, BioNTech will receive licensed rights for two of Duality Biologics' antibody-drug conjugate candidates targeting solid tumors.

This is an updated version of an article originally published by the Investing News Network in 2016.

Don’t forget to follow us @INN_LifeScience for real-time news updates!

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

The Conversation (0)

How to Invest in Biotech:


S&P 5004263.97-24.08


Heating Oil3.22-0.08
Natural Gas2.84-0.09